Basu Partha, Muwonge Richard, Bhatla Neerja, Nene Bhagwan M, Joshi Smita, Esmy Pulikottil O, Poli Usha Rani Reddy, Joshi Geeta, Verma Yogesh, Zomawia Eric, Shastri Surendra S, Pimple Sharmila, Anantharaman Devasena, Prabhu Priya R, Hingmire Sanjay, Sauvaget Catherine, Lucas Eric, Pawlita Michael, Gheit Tarik, Jayant Kasturi, Malvi Sylla G, Siddiqi Maqsood, Michel Angelika, Butt Julia, Sankaran Subha, Rameshwari Ammal Kannan Thiraviam Pillai, Varghese Rintu, Divate Uma, Willhauck-Fleckenstein Martina, Waterboer Tim, Müller Martin, Sehr Peter, Vashist Shachi, Mishra Gauravi, Jadhav Radhika, Thorat Ranjit, Tommasino Massimo, Pillai M Radhakrishna, Sankaranarayanan Rengaswamy
Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
Papillomavirus Res. 2019 Jun;7:75-81. doi: 10.1016/j.pvr.2019.01.004. Epub 2019 Jan 31.
Earlier publication from the ongoing multi-centric study of the International Agency for Research on Cancer to evaluate less than three doses of the quadrivalent Human Papillomavirus (HPV) vaccine in India amongst unmarried girls demonstrated non-inferior total antibody titres, neutralizing antibody titres and antibody avidity in 2-dose recipients compared to 3-dose recipients at 15-18 years of age (Bhatla et al., 2018) [7]. The number of participants recruited at 15-18 years of age was 1515 and 1795 in the 3-dose and the 2-dose groups respectively. At a median follow-up of 7 years, incident HPV 16/18 infections were detected in 1.6% women receiving two doses and 0.8% women receiving three doses at 15-18 years. Frequency of incident infection was 7.0% in the age- and site-matched unvaccinated women (N = 1484). No persistent infection from HPV 16 was observed in the 2- or 3-dose recipients and one (0.2%) persistent HPV 18 infection was documented, each in the 3-dose and 2-dose cohorts. Among the unvaccinated women, the frequency of HPV 16/18 persistent infection was 1.7%. The protection offered by two doses of quadrivalent HPV vaccine against incident and persistent infections in recipients at 15-18 years is comparable to that seen in 3-dose recipients at 15-18 years.
国际癌症研究机构正在进行的一项多中心研究早期发表的成果显示，在印度未婚女孩中评估三剂次以下四价人乳头瘤病毒（HPV）疫苗效果时，15至18岁的两剂次接种者与三剂次接种者相比，其总抗体滴度、中和抗体滴度及抗体亲和力均无劣势（Bhatla等人，2018年）[7]。15至18岁组中，三剂次组招募了1515名参与者，两剂次组招募了1795名参与者。中位随访7年后，15至18岁接种两剂次的女性中，HPV 16/18感染发生率为1.6%，接种三剂次的女性中为0.8%。年龄和部位匹配的未接种疫苗女性（N = 1484）的感染发生率为7.0%。两剂次或三剂次接种者均未观察到HPV 16持续感染，三剂次组和两剂次组各有一例（0.2%）HPV 18持续感染记录。在未接种疫苗的女性中，HPV 16/18持续感染发生率为1.7%。两剂次四价HPV疫苗对15至18岁接种者预防新发感染和持续感染的效果与15至18岁接种三剂次者相当。
